Results 111 to 120 of about 119,808 (291)

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome

Epilepsia, EarlyView.
Overview of the phase 3 trial evaluating soticlestat as adjunctive therapy in children and young adults with Dravet syndrome. Abstract Objective This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS).
Joseph Sullivan, Kette Valente, Vicente Villanueva, Adam Strzelczyk, Rima Nabbout, Eiji Nakagawa, Yuehua Zhang, Marta Zolnowska, Yasir Khan, Cheng Dong, Samuel Hsiao, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Venkatesha Murthy   +14 more
wiley   +1 more source

Focal seizures during simulated driving: A pilot study

Epilepsia, EarlyView.
Abstract Cars are increasingly equipped with technology that can be used to analyze driver behavior and alertness, often referred to as driver monitoring systems (DMS). Although initially mainly used to track drivers' attention, DMS are now expanding in the hope of detecting additional forms of driver impairment that may jeopardize driving, such as ...
Emma Nilsson, Mirta Zelenika Zeba, Joakim Strandberg, Peter Lundgren, Johan Zelano   +4 more
wiley   +1 more source

A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome

Epilepsia, EarlyView.
Soticlestat as adjunctive therapy for Lennox–Gastaut syndrome. Abstract Objective There remains a need for new treatments for Lennox–Gastaut syndrome (LGS), a developmental and epileptic encephalopathy with a heterogenous patient population that often requires polytherapy. The phase 3, randomized SKYWAY study (NCT04938427) investigated the efficacy and
Renzo Guerrini, Eric D. Marsh, Wei‐Ping Liao, Katsumi Imai, Ruzica Kravljanac, Anna Altmann, Cecil D. Hahn, Stéphane Auvin, Jimmy Schiemann, Yasir Khan, Pranab Mitra, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Dennis Dlugos, Venkatesha Murthy   +15 more
wiley   +1 more source

The Comparison of Gabapentin and Amitriptilin Effectivity as Pain Therapy in Herniated Nucleus Pulposus [PDF]

, 2015
Herniated nucleus pulposus (HNP) is one of peripheral neuropathic pain. Although concensus guidelines for the treatment of neuropathic pain are based on the results of the RCT studies, there are still gaps in the literatures.
Cahyaningsih, I. (Indriastuti), Handayani, R. (Rina), Setyaningsih, S. (Setyaningsih)   +2 more
core  

Fenfluramine in SCN1A‐related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability

Epilepsia Open, EarlyView.
Abstract The SCN1A gene is implicated in a broad spectrum of epilepsy phenotypes, ranging from self‐limited genetic epilepsy with febrile seizures plus (GEFS+) to severe developmental and epileptic encephalopathies such as Dravet syndrome (DS). While fenfluramine (FFA) has demonstrated strong efficacy in DS, its role in SCN1A‐related epilepsies beyond ...
Giovanni B. Dell'Isola, Alice Muda, Lucio Giordano, Renzo Guerrini, Alessandra Boncristiano, Nicola Pietrafusa, Maria Polselli, Francesca Bisulli, Francesca Ragona, Antonella Riva, Pasquale Striano, Domenica Immacolata Battaglia, Federico Vigevano   +12 more
wiley   +1 more source

Managing driver fatigue: education or motivation? [PDF]

, 2010
Fatigue has been recognised as the primary contributing factor in approximately 15% of all fatal road crashes in Australia. To develop effective countermeasures for managing fatigue, this study investigates why drivers continue to drive when sleepy, and ...
Armstrong, Kerry, Banks, Tamara, Obst, Patricia, Smith, Simon   +3 more
core   +1 more source

Highly purified cannabidiol (CBD) in CDKL5 deficiency disorder (CDD): Open‐label prospective study

Epilepsia Open, EarlyView.
Abstract Objective CDKL5 deficiency disorder (CDD) is an early‐onset developmental and epileptic encephalopathy characterized by frequent drug‐resistant seizures, cerebral visual impairment, motor dysfunction, and sleep and gastrointestinal disturbances.
Marco Perulli, Alessia De Gioia, Federica Ruggiero, Federica Ascione, Chiara Porto, Elisa Musto, Valentina Massaroni, Maria Picilli, Maria Luigia Gambardella, Michela Quintiliani, Ilaria Contaldo, Chiara Veredice, Domenica Immacolata Battaglia   +12 more
wiley   +1 more source

Sialidosis type I: How to alleviate disabling myoclonic seizures?—A multicenter analysis of eight cases and review of the literature

Epilepsia Open, EarlyView.
Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Janina Gburek‐Augustat, I‐Chun Lee, Marica Rubino, Vehap Topçu, Melissa Chavez‐Castillo, Shao Ching Tu, Marwan Shinawi, Isabel Alfradique‐Dunham, Manouela Valtcheva, Astrid Adarmes‐Gómez, Daniel Macias‐Garcia, Laura Laura Muñoz‐Delgado, Silvia Jesús, Pablo Mir, Andreas Merkenschlager, Antonietta Coppola   +15 more
wiley   +1 more source

Not Just an Ache: Examining the Rate of Musculoskeletal Pain in City Bus Drivers [PDF]

, 2018
This paper examines the rates of musculoskeletal discomfort in a sample of 957 city bus drivers at King County Metro, a public transportation agency serving the greater Seattle area. It also examines how often such pain prevented drivers from doing their
Steele, Jeremy
core   +1 more source